EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease: clinical and therapeutic considerations

Onanong Phokaewvarangkul iD, Roongroj Bhidayasiri iD, Pedro Garcia-Ruiz iD, Per Odin iD, Peter Riederer iD, Thomas Müller iD

Journal of Neural Transmission · 2023-11 · 130 (11) · 1451-1462

DOI: 10.1007/s00702-023-02684-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neural Transmission, online erschienen am 21.08.2023. Verfasst von Onanong Phokaewvarangkul und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University…. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 97 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emerging studies suggest a correlation between elevated plasma homocysteine (hcy) levels and the risk of atherosclerosis, vascular disorders, and neurodegenerative diseases, including Parkinson's disease (PD). This narrative review delves into the intricate relationships between Hcy, vitamin B metabolites, dopamine-substituting compounds, and various symptoms of PD. Patients undergoing a long-term L-dopa/dopa-decarboxylase inhibitor (DDI) regimen, especially without a concurrent catechol-O-methyl transferase (COMT) inhibitor or methyl group-donating vitamin supplementation, such as vitamins B6 and B12, exhibit an elevation in Hcy and a decline in vitamin B metabolites. These altered concentrations appear to be associated with heightened risks of developing non-motor symptoms, including peripheral neuropathy and cognitive disturbances. The review underscores the impact of levodopa metabolism via COMT on homocysteine levels. In light of these findings, we advocate for the supplementation of methyl group-donating vitamins, notably B6 and B12, in patients undergoing a high-dose L-dopa/DDI regimen, particularly those treated with L-dopa/carbidopa intestinal gel (LCIG) infusion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevodopaParkinson DiseaseHumansAntiparkinson AgentsDopamineCatechol O-MethyltransferaseHomocysteineVitaminsVitamin B 12

Stichwörter der Autor:innen

HomocysteineLevodopaNeuropathyParkinson’s diseaseVitamin B metabolites

Substanzen

LevodopaAntiparkinson AgentsDopamineCatechol O-MethyltransferaseHomocysteineVitaminsVitamin B 12

Autor:innen und Institutionen

  • Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 187…
  • The Academy of Science, The Royal Society of Thailand, Bangkok, 10330, Thailand. rbh@chulapd.org.
  • Movement Disorders Unit, Department of Neurology, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain.
  • Division of Neurology, Department of Clinical Sciences Lund, Restorative Parkinson Unit, Lund University, 221 84, Lund, Sweden.
  • Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital Würzburg, Margarete-Höppel Platz 1, 97080, Würzburg, Germany.
  • Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Gartenstr. 1, 13088, Berlin, Germany.

ORCID-Profile: Onanong Phokaewvarangkul, Roongroj Bhidayasiri, Pedro Garcia-Ruiz, Per Odin, Peter Riederer, Thomas Müller

Zitieren

APA

Phokaewvarangkul, O., Bhidayasiri, R., Garcia-Ruiz, P., Odin, P., Riederer, P., & Müller, T. (2023). Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease: clinical and therapeutic considerations. Journal of Neural Transmission, 130(11), 1451-1462. https://doi.org/10.1007/s00702-023-02684-9

Vancouver

Phokaewvarangkul O, Bhidayasiri R, Garcia-Ruiz P, Odin P, Riederer P, Müller T. Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease: clinical and therapeutic considerations. Journal of Neural Transmission. 2023;130(11):1451-1462. doi:10.1007/s00702-023-02684-9

BibTeX
@article{Phokaewvarangkul2023,
  author = {Phokaewvarangkul, Onanong and Bhidayasiri, Roongroj and Garcia-Ruiz, Pedro and Odin, Per and Riederer, Peter and Müller, Thomas},
  title = {Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease: clinical and therapeutic considerations},
  journal = {Journal of Neural Transmission},
  year = {2023},
  volume = {130},
  number = {11},
  pages = {1451--1462},
  doi = {10.1007/s00702-023-02684-9}
}
Kostenlos starten →